格隆汇9月9日丨石四药集团(02005.HK)公告，集团的吲哚菁绿已获中国国家药品监督管理局批准登记成 为在上市制剂使用的原料药。吲哚菁绿可用于诊断肝硬化、肝纤维化、韧性肝炎、职业和药物中毒性肝 病等各种肝脏疾病，了解肝脏的损害程度及其储备功能;亦可用于脉络膜血管造影，确定脉络膜疾患的 位置。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 吲哚菁綠可用於診斷肝硬化、肝纖維化、韌性肝炎、職業和藥物中毒性肝病等各種肝臟疾病， 瞭解肝臟的損害程度及其儲備功能; 亦可用於脈絡膜血管造影，確定脈絡膜疾患的位置。 本公告為本公司自願發佈，目的是使股東及潛在投資者瞭解本集團最新業務發展情況。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年九月九日 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本集團」）董事局（「董事局」）欣然公告， 本集團的吲哚菁綠已獲中國國家藥品監督管理局批准登記成為在上市製劑使用的原料藥。 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 ...

Core Viewpoint - The executive director, chairman, and CEO of China Pharmaceutical (石四药集团) increased his shareholding by acquiring 440,000 shares at an average price of HKD 3.2797 per share, totaling approximately HKD 1.4431 million, resulting in a slight increase in his ownership percentage from 39.70% to 39.72% [1][2]. Group 1 - The executive director and CEO, 曲继广, purchased 440,000 shares of China Pharmaceutical on September 8, 2025 [1][3]. - The total investment for the share purchase was about HKD 1.4431 million [1]. - Following the acquisition, 曲继广's total shareholding reached 1,172,182,000 shares [1][2].

Group 1 - The latest shareholder equity disclosure for Stone Four Pharmaceutical Group (02005) and BYD Electronic (00285) was conducted on September 8, 2025 [1] Group 2 - For Stone Four Pharmaceutical Group (02005), China Pharmaceutical Company Limited increased its holdings from 878 million shares to 881 million shares, representing a holding percentage change from 29.77% to 29.83% [2] - Qu Jiguang also increased his holdings in Stone Four Pharmaceutical Group from 1.17 billion shares to 1.172 billion shares, maintaining a holding percentage of 39.70% [2] - For BYD Electronic (00285), Jiang Xiangrong increased his holdings from 262,000 shares to 270,000 shares, with a holding percentage remaining at 0.01% [2]

Group 1 - The core point of the news is that Qu Jiguang, the Executive Director, Chairman, and CEO of Stone Four Pharmaceutical Group, increased his shareholding by purchasing 1.88 million shares at an average price of HKD 3.0859 per share, totaling approximately HKD 5.8015 million [1] - Following this transaction, Qu Jiguang's total shareholding increased to 1,171,742,000 shares, raising his ownership percentage from 39.64% to 39.70% [1][2] Group 2 - The transaction occurred on September 5, 2025, and was disclosed in the latest equity disclosure documents from the Hong Kong Stock Exchange [1] - The average price per share for the purchase was HKD 3.0859, indicating a strategic investment by the executive [2]

Core Viewpoint - The company Shijiazhuang Pharmaceutical Group has received production registration approvals from the National Medical Products Administration for seven pharmaceutical products, indicating a significant advancement in its product portfolio and market positioning [1]. Group 1: Product Approvals - The company has obtained approvals for the following products: 1. Arginine Perindopril Tablets (10mg), classified as a Class 4 chemical drug, is the second domestic company to receive approval, primarily used for treating hypertension and congestive heart failure [1]. 2. Progesterone Injection (II) (1.112ml:25mg), classified as a Class 3 chemical drug, is used for progesterone supplementation in assisted reproductive technology (ART) [1]. 3. Labetalol Hydrochloride Injection (20ml:100mg), classified as a Class 3 chemical drug, is used for various types of hypertension, especially hypertensive crises, and for blood pressure control before surgery [1]. 4. Calcium Chloride Injection (10ml:1g), classified as a Class 3 chemical drug, is primarily used for treating acute hypocalcemia and magnesium poisoning [1]. 5. Compound Electrolyte Acetate Injection (500ml), classified as a Class 3 chemical drug, is used for treating isotonic dehydration with mild acidosis and for replenishing extracellular fluid and blood volume loss [1]. 6. Compound Electrolyte Injection (V) (500ml), classified as a Class 3 chemical drug, serves as a source of water and electrolytes for adults [1]. 7. Levosalbutamol Hydrochloride Nebulization Solution (3ml:0.63mg), classified as a Class 3 chemical drug, is used for treating or preventing bronchospasm in adults and children over six years old with reversible airway obstructive diseases [1].

智通财经APP讯，石四药集团(02005)发布公告，集团已取得国家药监局有关下列共7个药品的药品生产 注册批件: (6) 复方电解质注射液(V)(500ml)，属于化学药品第3类，视同通过一致性评价。复方电解质注射液主要 用于成人作为水、电解质的补充源和硷化剂;及 (7) 盐酸左沙丁胺醇雾化吸入溶液(3ml: 0.63mg)，属于化学药品第3类，视同通过一致性评价。盐酸左沙 丁胺醇雾化吸入溶液主要用于治疗或预防成人及6岁以上儿童可逆性气道阻塞性疾病引起的支气管痉 挛。集团的盐酸左沙丁胺醇原料药已获国家药监局批准登记成为在上市制剂使用的原料药。 (3) 盐酸拉贝洛尔注射液(20ml: 100mg)，属于化学药品第3类，视同通过一致性评价。盐酸拉贝洛尔注射 液主要用于各种类型高血压(尤其是高血压危象)的治疗、外科手术前控制血压、嗜铬细胞瘤的降压治疗 及妊娠高血压; (4) 氯化钙注射液(10ml: 1g)，属于化学药品第3类，视同通过一致性评价。氯化钙注射液主要治疗急性 低钙血症及镁中毒; (5) 复方电解质醋酸钠注射液(500ml)，属于化学药品第3类，视同通过一致性评价。复方电解质醋酸钠 注射液主要用于治疗伴 ...

Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group, has received production registration approvals from the National Medical Products Administration for seven pharmaceutical products, indicating a significant advancement in its product portfolio and market positioning [1]. Group 1: Product Approvals - The company has obtained approvals for the following seven drugs: 1. Arginine Perindopril Tablets (10mg), classified as a Class 4 chemical drug, is the second domestic company to receive approval, primarily used for treating hypertension and congestive heart failure [1]. 2. Progesterone Injection (II) (1.112ml: 25mg), classified as a Class 3 chemical drug, is used for progesterone supplementation in assisted reproductive technology (ART) [1]. 3. Labetalol Hydrochloride Injection (20ml: 100mg), classified as a Class 3 chemical drug, is indicated for various types of hypertension, especially hypertensive crises, and for blood pressure control before surgery [1]. 4. Calcium Chloride Injection (10ml: 1g), classified as a Class 3 chemical drug, is primarily used for treating acute hypocalcemia and magnesium poisoning [1]. 5. Compound Electrolyte Acetate Injection (500ml), classified as a Class 3 chemical drug, is used for treating isotonic dehydration with mild acidosis and for replenishing extracellular fluid and blood volume loss [1]. 6. Compound Electrolyte Injection (V) (500ml), classified as a Class 3 chemical drug, serves as a source of water and electrolytes for adults [1]. 7. Levosalbutamol Nebulization Solution (3ml: 0.63mg), classified as a Class 3 chemical drug, is used for treating or preventing bronchospasm in adults and children over 6 years old with reversible airway obstructive diseases [1].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 承董事局命 執行董事兼公司秘書 周興揚 香港，二零二五年九月五日 於本公告日期，董事局成員包括執行董事曲繼廣先生、蘇學軍先生、孟國先生、周興揚先生及 曲婉蓉女士，非執行董事劉文軍先生，以及獨立非執行董事王亦兵先生、周國偉先生及姜廣策 先生。 (6) 複方電解質注射液(V) (500ml)，屬於化學藥品第3類，視同通過一致性評價。複方電解質注 射液主要用於成人作為水、電解質的補充源和鹼化劑;及 (7) 鹽酸左沙丁胺醇霧化吸入溶液(3ml: 0.63mg)，屬於化學藥品第3類，視同通過一致性評價。 鹽酸左沙丁胺醇霧化吸入溶液主要用於治療或預防成人及6歲以上兒童可逆性氣道阻塞性 疾病引起的支氣管痙攣。誠如本公司日期為二零二三年九月四日之公告所載，本集團的鹽 酸左沙丁胺醇原料藥已獲國家藥監局批准登記成為在上市製劑使用的原料藥。 自願公告 產品開發的最新進展 石四藥集團有限公司（「本公司」，連同其附屬公司，「本 ...

Group 1 - The core point of the article is that 石四药集团 (Shijiazhuang Pharmaceutical Group) has seen a significant stock price increase of nearly 14% following the announcement of obtaining production registration approvals for two pharmaceutical products from the National Medical Products Administration of China [1] - The company has received production registration approvals for 乌拉地尔缓释胶囊 (Urapidil Sustained-release Capsules, 30mg) and 盐酸尼卡地平氯化钠注射液 (Nicardipine Hydrochloride Sodium Injection, 200ml), both classified as Category 3 chemical drugs, marking them as the first domestic company to receive such approvals [1] - Additionally, the company has obtained production registration approval for 盐酸屈他维林注射液 (Sufentanil Hydrochloride Injection, 2ml), classified as a Category 4 chemical drug, also indicating successful consistency evaluation [1] Group 2 - Citigroup's research report indicates that in the 11th round of drug procurement, 石四药集团 has 11 drugs, including Bromhexine, which is expected to account for approximately 1.5% of projected sales in 2024 [1] - The report suggests that the company has a strong chance of winning contracts for peritoneal dialysis solutions and renewing contracts for other products [1] - Citigroup views 石四药集团 as a winner among generic drug companies and the largest beneficiary of drug procurement policies [1]